Market capitalization | $154.27m |
Enterprise Value | $131.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 34.07 |
P/S ratio (TTM) P/S ratio | 40.07 |
P/B ratio (TTM) P/B ratio | 1.44 |
Revenue growth (TTM) Revenue growth | 550.76% |
Revenue (TTM) Revenue | $3.85m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
12 Analysts have issued a Prime Medicine forecast:
12 Analysts have issued a Prime Medicine forecast:
Mar '25 |
+/-
%
|
||
Revenue | 3.85 3.85 |
553%
553%
|
|
Gross Profit | -2.67 -2.67 |
76%
76%
|
|
EBITDA | -200 -200 |
6%
6%
|
EBIT (Operating Income) EBIT | -207 -207 |
3%
3%
|
Net Profit | -202 -202 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Keith Gottesdiener |
Employees | 214 |
Founded | 2019 |
Website | www.primemedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.